Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy Journal Article


Authors: Rudloff, U.; Brogi, E.; Brockway, J. P.; Goldberg, J. I.; Cranor, M.; Wynveen, C. A.; Nehhozina, T.; Reiner, A. S.; Patil, S.; Van Zee, K. J.
Article Title: Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy
Abstract: BACKGROUND: Multiple clinicopathologic factors have been analyzed for their association with an increased risk of ipsilateral breast tumor recurrence (IBTR) after women receive breast-conserving treatment (BCT) for ductal carcinoma in situ (DCIS). The reported incidence of proliferative lesions, such as atypical ductal hyperplasia (ADH), columnar cell changes (CCC), and lobular neoplasia associated with breast cancer, has been as high as 23%; however, the relevance of these lesions on the natural history of DCIS and the risk of IBTR remains unknown. METHODS: Two hundred ninety-four patients with DCIS who received BCT between 1991 and 1995 were identified from the authors' institutional database. Slides were reviewed by a dedicated breast pathologist with particular attention to the presence of lobular neoplasia, ADH, and CCC. The actuarial 5-, 10-, and 15-year IBTR rates were calculated using the Kaplan-Meier method and were compared using the log-rank test. RESULTS: Concurrent lobular neoplasia was present in 41 of 294 patients (14%), ADH was present in 37 of 294 patients (13%), and CCC was present in 71 of 294 patients (24%). The median follow-up was 11 years. IBTR occurred in 40 of 227 patients without lobular neoplasia (18%) versus 15 of 41 patients with lobular neoplasia (37%; P = .005; hazard ratio [HR], 2.49). The 5-, 10-, and 15-year cumulative incidence rates of IBTR were twice as high in women who had DCIS and lobular neoplasia compared with women who had DCIS alone (P = .002). Concomitant ADH (HR, 1.53) and CCC (HR, 1.24) were not associated significantly with IBTR (P = .20 and P = .44, respectively). CONCLUSIONS: Concurrent lobular neoplasia is associated with a significantly higher risk of IBTR in women with DCIS who received BCT. Women with coexisting DCIS and lobular neoplasia who receive BCT should consider using additional risk-reducing strategies. © 2009 American Cancer Society.
Keywords: adult; cancer survival; controlled study; aged; middle aged; major clinical study; cancer recurrence; cancer risk; adjuvant therapy; cancer radiotherapy; comparative study; follow up; breast cancer; breast; incidence; recurrence; breast neoplasms; risk assessment; lung tumor; hyperplasia; neoplasm metastasis; tamoxifen; kaplan meier method; intraductal carcinoma; neoplasms, multiple primary; carcinoma, intraductal, noninfiltrating; mastectomy, segmental; ductal carcinoma in situ; lobular carcinoma in situ; lobular neoplasia; breast conservation; high-risk proliferative breast cancer lesions; ipsilateral breast tumor recurrence; log rank test; carcinoma, lobular
Journal Title: Cancer
Volume: 115
Issue: 6
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2009-03-15
Start Page: 1203
End Page: 1214
Language: English
DOI: 10.1002/cncr.24166
PUBMED: 19170233
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 2" - "Export Date: 30 November 2010" - "CODEN: CANCA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sujata Patil
    511 Patil
  2. Anne S Reiner
    251 Reiner
  3. Kimberly J Van Zee
    293 Van Zee
  4. Udo Rudloff
    12 Rudloff
  5. Edi Brogi
    520 Brogi
  6. Christine Ann Wynveen
    11 Wynveen
  7. Milicent Cranor
    48 Cranor